Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The Company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. It also has a clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The Company's pipeline also includes PALSONIFY (paltusotine) and atumelnant. PALSONIFY is the once-daily oral therapy for acromegaly.
Back to dashboard
Company Information
About this company
Key people
Jeffrey M. Leiden
Executive Chairman of the Board
Ourania Tatsis
Executive Vice President, Chief Regulatory and Quality Officer
Bruce I. Sachs
Lead Independent Director
Sangeeta N. Bhatia
Independent Director
Lloyd A. Carney
Independent Director
Alan Garber
Independent Director
Michel Lagarde
Independent Director
Reshma Kewalramani
President, Chief Executive Officer, Director
Charles F. Wagner
Chief Operating Officer, Executive Vice President
E. Morrow Atkinson
Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operations
Jonathan Biller
Executive Vice President, Chief Legal Officer
Carmen Bozic
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Mark E. Bunnage
Executive Vice President, Chief Scientific Officer
Duncan J. Mckechnie
Executive Vice President, Chief Commercial Officer
Amit K. Sachdev
Executive Vice President, Chief Patient and External Affairs Officer
Click to see more
Key facts
- Shares in issue253.46m
- EPICVRTX
- ISINUS92532F1003
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$138.42bn
- Employees6,400
- ExchangeNASDAQ
- IndexS&P 500, NASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.